Oscar Arrieta, Alexandra Díaz-Alba, Sergio Moreno-Jiménez, Alejandro Rodríguez-Camacho, Enrique Caballe-Pérez, Marco Antonio Rodríguez-Florido, Alberto González-Aguilar, Ytel Garcilazo-Reyes, Mónica Alicia Sierra-Del-Río, Fernando Alcides Lozano-Sánchez, Bernardo Cacho-Díaz
{"title":"中枢神经系统转移患者的真实体验结果：15年期间2226例患者的信息。","authors":"Oscar Arrieta, Alexandra Díaz-Alba, Sergio Moreno-Jiménez, Alejandro Rodríguez-Camacho, Enrique Caballe-Pérez, Marco Antonio Rodríguez-Florido, Alberto González-Aguilar, Ytel Garcilazo-Reyes, Mónica Alicia Sierra-Del-Río, Fernando Alcides Lozano-Sánchez, Bernardo Cacho-Díaz","doi":"10.1007/s11060-025-05190-y","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Most data regarding Central nervous system (CNS) metastases are derived from non-Hispanic populations enrolled in clinical trials. This study aims to characterize the primary tumors, initial treatments, and outcomes in a Hispanic/Latino real-world population with CNS metastases.</p><p><strong>Methods: </strong>A retrospective analysis of a multicenter cohort of patients with CNS metastases treated from 2010 to 2024.</p><p><strong>Results: </strong>From 2,261 patients with CNS metastases, 84% had brain metastases and 16% had neoplastic meningitis. The most common primary tumors were breast (40%), lung (27%), genitourinary (11%), gynecologic (6%), and melanoma (4%). Whole-brain radiotherapy and systemic therapy were initially prescribed in 84% and 55% of cases, respectively. The median overall survival was 9.8 months (95% CI, 8.9 - 10.7). Variables associated with outcomes included location of the primary tumor, molecular subtype, type of CNS metastases (brain metastases vs. neoplastic meningitis), and access to targeted therapies.</p><p><strong>Conclusion: </strong>In a real-world cohort of Hispanic/Latino patients with CNS metastases, survival has remained poor over the past 15 years. This highlights the need for interventions and research to improve outcomes.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":" ","pages":"1227-1234"},"PeriodicalIF":3.1000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Real-world experience outcome in patients with central nervous system metastases: information on 2,226 patients during a 15-year period.\",\"authors\":\"Oscar Arrieta, Alexandra Díaz-Alba, Sergio Moreno-Jiménez, Alejandro Rodríguez-Camacho, Enrique Caballe-Pérez, Marco Antonio Rodríguez-Florido, Alberto González-Aguilar, Ytel Garcilazo-Reyes, Mónica Alicia Sierra-Del-Río, Fernando Alcides Lozano-Sánchez, Bernardo Cacho-Díaz\",\"doi\":\"10.1007/s11060-025-05190-y\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>Most data regarding Central nervous system (CNS) metastases are derived from non-Hispanic populations enrolled in clinical trials. This study aims to characterize the primary tumors, initial treatments, and outcomes in a Hispanic/Latino real-world population with CNS metastases.</p><p><strong>Methods: </strong>A retrospective analysis of a multicenter cohort of patients with CNS metastases treated from 2010 to 2024.</p><p><strong>Results: </strong>From 2,261 patients with CNS metastases, 84% had brain metastases and 16% had neoplastic meningitis. The most common primary tumors were breast (40%), lung (27%), genitourinary (11%), gynecologic (6%), and melanoma (4%). Whole-brain radiotherapy and systemic therapy were initially prescribed in 84% and 55% of cases, respectively. The median overall survival was 9.8 months (95% CI, 8.9 - 10.7). Variables associated with outcomes included location of the primary tumor, molecular subtype, type of CNS metastases (brain metastases vs. neoplastic meningitis), and access to targeted therapies.</p><p><strong>Conclusion: </strong>In a real-world cohort of Hispanic/Latino patients with CNS metastases, survival has remained poor over the past 15 years. This highlights the need for interventions and research to improve outcomes.</p>\",\"PeriodicalId\":16425,\"journal\":{\"name\":\"Journal of Neuro-Oncology\",\"volume\":\" \",\"pages\":\"1227-1234\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2025-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Neuro-Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s11060-025-05190-y\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/8/13 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Neuro-Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11060-025-05190-y","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/13 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
Real-world experience outcome in patients with central nervous system metastases: information on 2,226 patients during a 15-year period.
Purpose: Most data regarding Central nervous system (CNS) metastases are derived from non-Hispanic populations enrolled in clinical trials. This study aims to characterize the primary tumors, initial treatments, and outcomes in a Hispanic/Latino real-world population with CNS metastases.
Methods: A retrospective analysis of a multicenter cohort of patients with CNS metastases treated from 2010 to 2024.
Results: From 2,261 patients with CNS metastases, 84% had brain metastases and 16% had neoplastic meningitis. The most common primary tumors were breast (40%), lung (27%), genitourinary (11%), gynecologic (6%), and melanoma (4%). Whole-brain radiotherapy and systemic therapy were initially prescribed in 84% and 55% of cases, respectively. The median overall survival was 9.8 months (95% CI, 8.9 - 10.7). Variables associated with outcomes included location of the primary tumor, molecular subtype, type of CNS metastases (brain metastases vs. neoplastic meningitis), and access to targeted therapies.
Conclusion: In a real-world cohort of Hispanic/Latino patients with CNS metastases, survival has remained poor over the past 15 years. This highlights the need for interventions and research to improve outcomes.
期刊介绍：
The Journal of Neuro-Oncology is a multi-disciplinary journal encompassing basic, applied, and clinical investigations in all research areas as they relate to cancer and the central nervous system. It provides a single forum for communication among neurologists, neurosurgeons, radiotherapists, medical oncologists, neuropathologists, neurodiagnosticians, and laboratory-based oncologists conducting relevant research. The Journal of Neuro-Oncology does not seek to isolate the field, but rather to focus the efforts of many disciplines in one publication through a format which pulls together these diverse interests. More than any other field of oncology, cancer of the central nervous system requires multi-disciplinary approaches. To alleviate having to scan dozens of journals of cell biology, pathology, laboratory and clinical endeavours, JNO is a periodical in which current, high-quality, relevant research in all aspects of neuro-oncology may be found.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
